GSK Neladalkib: Nov 27 ALK NSCLC PDUFA Primer

GSK closed at $52.96 with a $104.5 billion market cap. It paid $10.6 billion for Nuvalent in July 2026, and the first asset from that deal, zidesamtinib, already won FDA approval for ROS1-positive NSCLC. The Jideytro FDA approval analysis covers what the approval means for the Nuvalent acquisition. Now the second asset, neladalkib, heads to a November 27 PDUFA for TKI-pretreated ALK-positive NSCLC. The question is not whether the FDA approves it. The question is whether a $500 million to $1 billion peak sales drug moves the needle on a $104 billion company. It does not. But the approval still matters: it validates the second half of the deal thesis and fills a gap in the ALK TKI sequencing chain that Pfizer’s lorlatinib currently owns.

The ALK TKI Market Is Real, and It Is Crowded

ALK-positive NSCLC accounts for 3% to 5% of all lung cancers, roughly 7,000 to 11,000 new US cases per year. These patients skew younger and are often never-smokers or light smokers. The standard of care is sequential ALK TKI therapy: alectinib first-line, lorlatinib on progression, with brigatinib and ceritinib as alternatives. The global ALK inhibitor market was worth approximately $3 billion in 2025.

Roche’s Alecensa owns the first-line setting with global sales of roughly $1.65 billion in 2023 and projections of $2.2 billion by 2029. Pfizer’s Lorbrena, a third-generation ALK TKI, crossed $1 billion in annual sales after the seven-year CROWN trial update showed a 94% reduction in intracranial progression risk versus crizotinib. Lorbrena is the current standard for post-alectinib progression. This is where neladalkib enters the picture: the TKI-pretreated setting, after patients have burned through alectinib and possibly lorlatinib.

This is the oncology catalyst calendar at work. The full 2026 oncology PDUFA and readout calendar is in the oncology catalysts roundup, and neladalkib is the last major targeted therapy decision of the year.

The ALKOVE-1 Data

The NDA rests on ALKOVE-1, a global single-arm Phase 1/2 trial that enrolled 656 patients with ALK-positive NSCLC (NCT05384626). Neladalkib was designed for coverage of the G1202R solvent-front mutation that drives resistance to earlier ALK TKIs, with brain penetrance to address CNS progression and a TRK-sparing selectivity profile that avoids lorlatinib’s neurological side effects.

The registrational dataset presented at ASCO 2026 covered 253 TKI-pretreated patients who had received a median of three prior anticancer therapies. Seventy-eight percent had received two or more prior ALK TKIs, and 91% of those had prior lorlatinib. Forty percent had CNS metastases at baseline. These are heavily pretreated patients with few options left.

Across all TKI-pretreated patients, neladalkib showed a confirmed ORR of 31% (79/253, 95% CI 26-37%) by blinded independent central review. Duration of response at 12 months was 64%, and the estimated 18-month DOR was 53%. In patients who had only received one prior second-generation ALK TKI, meaning they were lorlatinib-naïve, ORR was 46% (29/63, 95% CI 33-59%) with a 12-month DOR of 80%.

The G1202R mutation data is where neladalkib earns its keep. Patients with single or compound G1202R mutations, the most common on-target resistance mutation after alectinib, had an ORR of 68% (32/47, 95% CI 53-81%). Preclinically, neladalkib is 57-fold more potent against ALK G1202R than lorlatinib (IC50 0.9 vs 51 nM), and it is the only ALK TKI active against the G1202R/L1196M compound mutation that confers resistance to all three generations of approved ALK TKIs.

Intracranial activity matters because CNS progression is the modal failure mode for ALK-positive NSCLC. Neladalkib produced an intracranial ORR of 32% (29/92) across all TKI-pretreated patients and 63% (15/24) in lorlatinib-naïve patients. Intracranial DOR at 12 months was 71% in the all-comers group and 92% in the lorlatinib-naïve group. For patients with prior lorlatinib, intracranial ORR was 21% (14/68), which is modest but real in a population with no remaining approved options.

Safety data, per the ASCO abstract, was “consistent with its ALK-selective, TRK-sparing design.” Translating from conference-speak: fewer grade 3-4 neurological adverse events than lorlatinib, which has well-documented neurocognitive toxicity requiring dose reductions in roughly 30% of patients. The TRK-sparing design is not a marketing point; it is the structural reason neladalkib can be given at full dose where lorlatinib cannot.

Competitive Picture

Neladalkib enters a market where Lorbrena already owns the post-alectinib slot. Pfizer’s CROWN data is excellent: seven years of follow-up, 94% lower intracranial progression risk, and the drug is embedded in NCCN guidelines as a preferred option. Alecensa holds the first line, and alectinib’s patent position means cheap generics are still years away.

The practical clinical question: after a patient fails alectinib, does the oncologist reach for Lorbrena or neladalkib? If the tumor has a G1202R mutation, the answer is neladalkib. If the patient has CNS disease and tolerability is a concern, the TRK-sparing profile tilts toward neladalkib. But if the patient has not yet tried lorlatinib, the seven-year CROWN data gives Pfizer a powerful marketing advantage that Nuvalent, now a GSK asset, cannot yet match with a single-arm Phase 1/2 dataset.

There is a precedent here: zidesamtinib got approved in ROS1-positive NSCLC based on single-arm data because the patient population is small and the unmet need is high. The ALK space is larger than ROS1, but the TKI-pretreated population where all approved options are exhausted is narrow. The FDA will likely approve on the ALKOVE-1 data, and the label scope, whether it covers all TKI-pretreated patients or restricts to specific prior lines, will be the commercial battleground.

Valuation: Large-Cap Immateriality

GSK generated £8.4 billion in Q2 2026 revenue, up 5% at constant currency, with specialty medicines growing 14%. Core operating profit was £2.8 billion. The full Q2 results, including the £1.9 billion cost-savings program and oncology pipeline, are covered in the GSK Q2 earnings analysis. Annual revenue runs at approximately $44 billion.

Neladalkib at peak sales of $500 million to $1 billion represents roughly 1% to 2% of GSK’s total revenue. Even in a best case where neladalkib displaces Lorbrena in the post-alectinib slot and peaks at $1.5 billion, the drug is 3% of revenue. GSK’s P/S ratio of roughly 2.4x annual revenue is in line with large-cap pharma comps: BMY at 2.6x, Sanofi at 1.9x, ABBV at 7.2x. This multiple reflects the patent cliff dynamics and pipeline mix, not the outcome of a single ALK TKI approval.

The stock has already priced the Nuvalent acquisition. Jideytro’s early approval in July 2026 did not move the stock materially, and neladalkib’s approval will not either. The deal thesis, buying two best-in-class targeted oncology assets from a small-cap developer, is a sound one for GSK’s long-term oncology buildout. But it is not a stock catalyst at $104 billion.

Risks

The primary risk is not clinical. It is commercial. The ALK TKI market has an entrenched standard of care with seven years of Phase 3 follow-up data. Neladalkib has single-arm Phase 1/2 data. A confirmatory Phase 3 trial, ALKAZAR, is enrolling but will not read out for years. In the meantime, Pfizer is not standing still: Lorbrena is being tested in earlier lines and in combinations. The window for neladalkib to establish itself is narrow.

The secondary risk is label scope. If the FDA restricts the label to patients who have failed lorlatinib, the addressable market shrinks from the full TKI-pretreated population to the truly last-line setting. That is a $200 million to $300 million market, not a $1 billion market. The FDA has precedent for narrow labels on single-arm data, and neladalkib’s ORR of 26% in prior-lorlatinib patients gives the agency a reason to be restrictive.

The third risk is the competitive pipeline. Other next-generation ALK TKIs, including TPX-0131 from Turning Point and Bristol Myers Squibb, are in development with similar mutation-coverage profiles. Neladalkib’s first-mover advantage in the G1202R space is real but not durable.

Verdict

GSK at $52.96 is a Hold. Neladalkib will likely be approved on November 27. The data is good: 31% ORR in heavily pretreated patients, 68% in G1202R-mutated tumors, intracranial activity durable past 12 months, and a safety profile that avoids lorlatinib’s neurotoxicity. The drug fills a clinical need and validates the second asset from the Nuvalent deal.

But approval is already priced into a $104 billion stock. If you want a tradable ALK TKI catalyst, look at a smaller pure-play where a single approval doubles the market cap. GSK does not trade on neladalkib. It trades on the HIV pipeline’s ability to extend patent protection past 2028. The RSV franchise and the £1.9 billion cost-savings program matter, but HIV is the structural question that determines whether GSK’s $44 billion revenue base holds or shrinks after the dolutegravir patent cliff. GSK’s oncology pipeline has had wins and losses this year, from Jideytro’s approval to the camlipixant CALM-2 Phase 3 failure covered in the GSK camlipixant analysis. Neladalkib is a win, but it is a win that fits inside the rounding error at GSK’s scale.

Check back in after November 27. If the label is broad and GSK’s oncology franchise shows sequential growth above 15%, the stock would earn a re-rating toward the large-cap pharma median of 3.5x sales, roughly 45% upside from here. If the label is narrow and oncology growth stalls, the stock stays where it is.

Correction note: The NDA was submitted by Nuvalent and the PDUFA date of November 27, 2026 was announced by Nuvalent in its May 27, 2026 press release. GSK acquired Nuvalent in July 2026. The drug is now a GSK asset.